

and the precipitated solid was collected by filtration. Recrystallization from cyclohexane gave 4.3 g (100%) of 32.

Diethyl [2-[4-(Benzothiazol-2-yl)phenoxy]ethyl]phosphonate (14). A mixture of chloride 32 (2.0 g, 0.0069 mol) and triethyl phosphite (3 mL) was heated at 190–200 °C for 5 h. After the reaction mixture had cooled, the precipitated solid was collected by filtration. The crude phosphonate was chromatographed on a silica gel column by eluting with a benzene/EtOAc mixture to give 1.5 g (56%) of 14. Recrystallization from cyclohexane yielded 14 as colorless needles: mp 93.0–94.0 °C.

Effect on Coronary Flow in the Isolated Guinea Pig Heart. Male guinea pigs of 400–500-g body weight were killed and exsanguinated and promptly thoracotomized. After cannulation of the ascending aorta, the heart was enucleated. The isolated heart was then perfused with Krebs–Henseleit fluid which was oxygenated with a gaseous mixture of 95% O₂ and 5% CO₂, at 34 ± 1 °C under a perfusion pressure of 60 cm of H₂O by the methods of Langendorff. The test compound, dissolved in propylene glycol to a concentration of 100 µg/mL, was then infused

at a rate of 0.1 mL/min. The coronary flow was measured with a square wave electromagnetic flow meter (Nihon Kohden, MF-26) with an extracorporeal probe (Nihon Kohden, FE) set at the top of the cannula and recorded with a multipurpose polygraph (Nihon Kohden, RM-85). The coronary flows before and after infusion were measured, and the percentage gain in coronary flow was obtained.

Registry No. 2, 41716-26-1; 3, 120332-20-9; 4, 2682-86-2; 5, 41806-42-2; 6, 120332-21-0; 7, 120332-22-1; 8, 120332-23-2; 9, 120332-24-3; 10, 83524-89-4; 11, 120332-25-4; 12, 120332-26-5; 13, 120332-27-6; 14, 120332-28-7; 15, 41806-41-1; 16, 41716-19-2; 17, 67273-40-9; 18, 2227-61-4; 19, 120332-29-8; 20, 23222-36-8; 21, 60-23-1; 22, 4434-13-3; 23, 120332-30-1; 24, 120332-31-2; 25, 120332-32-3; 26, 19654-19-4; 27, 2182-80-1; 28, 1660-94-2; 29, 120332-33-4; 30, 6265-55-0; 31, 84396-09-8; 32, 84396-10-1; triethyl phosphite, 122-52-1; 2-(benzimidazol-2-yl)-5-(bromomethyl)pyridine, 120332-34-5; diethyl phosphite, 762-04-9; fostedil, 75889-62-2.

Diethylstilbestrol-Linked Cytotoxic Agents: Synthesis and Binding Affinity for Estrogen Receptors

Karsten Krohn,*† Konrad Kulikowski,† and Guy Leclercq‡


Institut für Organische Chemie der Universität Braunschweig, Hagenring 30, D-3300 Braunschweig, Federal Republic of Germany, and Laboratoire de Cancérologie mammaire, Service de Médecine, Institut J. Bordet, 1000 Brussels, Belgium. Received August 16, 1988

The syntheses of diethylstilbestrol derivatives with a C₄ side chain at the double bond bearing various functional and potentially alkylating groups (9–25, 38–40, 43, 44) as well as the coupling product with daunorubicine (41) are described. Derivatives with *free* phenolic groups show easy isomerization to (*Z*)-stilbenes and styrenes, which could be minimized with silyl protecting groups. Estrogen receptor binding is decreased by polar groups such as carboxylic acids (10) as well as sterically demanding substituents.

The chemotherapy of cancer in its present form suffers from the fact that, in principle, no difference is made between normal and tumor cells, regardless of whether the drug belongs to the group of alkylants, enzyme inhibitors, or DNA intercalators.¹ A certain degree of selectivity is mainly due to the higher sensitivity of rapidly growing cells to various kinds of toxic compounds. Numerous efforts have been made to increase the selectivity toward cells and to decrease the systemic toxicity. A possibility for selectivity is offered by hormone-dependent tumors, such as certain breast tumors, which selectively concentrate natural and synthetic estrogens.² The idea to induce cytotoxic effects to hormone-dependent tumor cells by covalent linkage of N-mustard groups to the steroidal skeleton was tested in the late sixties.³ Since that time many compounds have been synthesized and tested in which various cytotoxic groups were linked to estradiol^{4–9} (1) (E₂), hexestrols^{10–13} (2) (HEX), diethylstilbestrols^{5,10–14} (3) (DES), or the antiestrogen tamoxifen¹⁵ (Chart I).

A prerequisite for specificity of these cytotoxic agents is a sufficient binding of the drug to the estrogen receptor, which allows the selective uptake into the hormone sensitive cells (relative binding affinity compared to E₂ = 100%; RBA). Calculations on the basis of the number of receptors per cell (about 1000–10000) and the possible drug concentration show that the RBA value should be at least 1% of that of E₂.¹⁶ However, chemical modification of estrogens usually produces a dramatic decrease in the binding affinity. Early work on the chemically easy derivatization of the hydroxy groups in E₂ (1), HEX (2), and

Chart I




DES (3) gave products with very low or no RBA, thus establishing the essential function of both hydroxy groups

- (1) Chabner, B. A.; Myers, C. E.; Coleman, C. N.; Johns, D. G. *N. Engl. J. Med.* 1975, 1107 and 1159.
- (2) Leclercq, G.; Heuson, J. C. *Anticancer Res.* 1981, 217, 1.
- (3) Wall, M. E.; Abernethy, G. S.; Carroll, F. I.; Taylor, D. J. *J. Med. Chem.* 1969, 12, 810.
- (4) Niculescu-Ducăz, I.; Cambanis, A.; Tăranăuceanu, E. *J. Med. Chem.* 1967, 10, 172.
- (5) Hamacher, H. *Arzneim.-Forsch./Drug Res.* 1979, 29, 463.
- (6) Hamacher, H. *Arzneim.-Forsch./Drug Res.* 1983, 33, 347.
- (7) Schönemann, K. H.; van Vliet, N. P.; Zeelen, F. J. *Eur. J. Med. Chem./Chim. Ther.* 1980, 15, 333.
- (8) Lam, A.; Begleiter, H. Y. P.; Goldenberg, G. J. *J. Med. Chem.* 1979, 22, 200.
- (9) Chesne, C.; Leclercq, G.; Pointeau, P.; Patin, H. *Eur. J. Med. Chem.-Chim. Ther.* 1986, 21, 3219.
- (10) Hamacher, H.; Brecht, B. *Arch. Pharm.* 1977, 310, 662.

*Institut für Organische Chemie der Universität Braunschweig.

†Institut J. Bordet.

Scheme I




in receptor binding.^{4,17} On the basis of these results and the fact that DES and HEX are known to have high RBA values¹⁸ we worked out a program to investigate the chemistry and receptor binding affinity of DES and HEX derivatives bearing longer chains in the middle part of the molecule remote from the essential hydroxy groups. Of particular interest was the investigation of the influence of side-chain length and polarity of substituents. The present paper on DES and the following on HEX report our observations in this regard, including information on the chemical synthesis of such compounds about which little has yet been published.^{19,20}

Chemistry

Starting Materials. The starting material for the synthesis of the side-chain DES derivatives was the acid **9** that was previously prepared in connection with a radioimmunoassay for DES.²¹ The synthesis is outlined in Scheme I and starts with the commercially available deoxyanisoin (**4**) that was alkylated with iodo ester **5** to yield **6**²² (for improvements on the original procedure, see the Experimental Section). The subsequent Grignard reaction of **6** with ethylmagnesium bromide gave a 92% yield of a 4:1 mixture of the threo and erythro esters **7** and **8**. Fortunately, the major isomer **7** could be isolated in pure

Chart II




form by crystallization. The stereocenters are lost on dehydration and both isomers **7** and **8** can be transformed to the corresponding stilbenes. On treatment with *p*-toluenesulfonic acid at 110 °C both dehydration and ester cleavage take place to afford a mixture of at least five compounds, the major components being the (*E*)- and (*Z*)-stilbenes **9a** and **9b** (65%) together with 35% of isomeric styrenes as shown by analysis of the 400-MHz ¹H NMR spectrum. A chromatographic purification of the most important (*E*)-stilbene methyl ether was possible. Styrene formation does not normally occur in the formation of DES, but it is known to take place with unsymmetrically substituted derivatives.²³ A simultaneous dehydration/ester and ether cleavage is effected by treatment with boron tribromide in dichloromethane²² or with potassium hydroxide in ethylene glycol at 200 °C²⁴ to afford phenolic acid **10** (90%) as a mixture of isomers as shown in Scheme I.

Our first goal was the synthesis of the DES alkyl halides which are potential alkylants. To this end acids **9a/9b** were reduced to alcohol **11** (mixture of isomers) with lithium aluminum hydride in 94% yield and converted to chloride **12** with triphenylphosphine/carbon tetrachloride²⁵ (Chart II). It was possible to purify pure (*E*)-stilbene **12** and also the other derivatives **13**–**18** from the reaction mixtures containing (*Z*)-stilbenes and styrenes by using a special TLC technique (see the Experimental Section). (Structural assignment was based on the chemical shift of the methyl group in the ¹H NMR spectrum at 0.77 ppm, which is characteristic for the *E* configuration²⁶). A one-step conversion of alcohol **11** to the corresponding iodide **13** was possible by using the method of Scheffold by treatment of **11** with *N,N*-dicyclohexyl-*N*-methyldicyclohexylcarbodiimide.²⁷ For binding studies it was of interest to include long-chain ethers, which were obtained by treatment of **11** with sodium hydride and ethyl iodide to afford the ethyl ether **14**. Longer aliphatic chains could be attached by alkylation of deoxyanisoin (**4**) with *n*-butyl bromide and *n*-octyl bromide followed by Grignardation with ethylmagnesium bromide and dehydration to provide intermediates **15** and **16**, respectively. The final stage of the reaction sequence was the liberation of the phenolic groups. Crystalline pure (*E*)-stilbenes **23** and **24** were isolated after methyl ether cleavage with BBr₃ or KOH.

- (11) Hamacher, H. *Arch. Pharm.* 1978, 311, 184.
- (12) Hamacher, H.; Mangold, C. *Arch. Pharm.* 1983, 316, 271.
- (13) Katzenellenbogen, J. A.; McGorin, R. J.; Tatee, T.; Kempton, R. J.; Carlson, K. E.; Kinder, D. H. *J. Med. Chem.* 1981, 24, 435.
- (14) Vilkas, M.; Epsztein, R.; Sainton, J.; Leclercq, G. *Eur. J. Med. Chem.-Chim. Ther.* 1982, 17, 191.
- (15) Wei, L. L.; Katzenellenbogen, B.; Robertson, D. W.; Sompson, D. M.; Katzenellenbogen, J. A. *Breast Cancer Res. Treat.* 1986, 7, 77.
- (16) Katzenellenbogen, J. A.; Katzenellenbogen, B. S. *Breast Cancer Res. Treat.* 1982, 2, 347.
- (17) Leclercq, G.; Heuson, J.-C. *Cancer Treatment Rep.* 1978, 62, 1255.
- (18) Péteri, E. *J. Chem. Soc.* 1940, 833.
- (19) Pons, M.; Michel, F.; de Paulet, A. C.; Gilbert, J.; Miquel, J.-F.; Précigoux, G.; Hospital, M.; Ojasoo, T.; Raunaud, J.-P. *J. Steroid. Biochem.* 1984, 20, 137.
- (20) Zablocki, J. A.; Katzenellenbogen, J. A.; Carlson, K. E.; Norman, M. J. *J. Med. Chem.* 1987, 30, 829.
- (21) Krohn, K. *Hoppe-Seyler's Z. Physiol. Chem.* 1977, 358, 1551.
- (22) Krohn, K.; Hemme, C. *Liebigs Ann. Chem.* 1978, 726.

- (23) Hamacher, H.; Bormann, B. *Arch. Pharm.* 1981, 314, 257.
- (24) Corse, J. U.S. Patent 2,325,307, July 27, 1943.
- (25) Appel, R. *Angew. Chem.* 1975, 87, 863; *Angew. Chem., Int. Ed. Engl.* 1975, 14, 801.
- (26) Winkler, V. W.; Nyman, M. A.; Egan, R. S. *Steroids* 1971, 17, 197.
- (27) Scheffold, R.; Saladin, E. *Angew. Chem.* 1972, 84, 158; *Angew. Chem., Int. Ed. Engl.* 1972, 11, 229.

Chart III



However, treatment of the alkali-labile halides 12 and 13 with BBr₃ and alcohol 11 and ether 14 with KOH at 200 °C resulted again in mixtures of (*E*)- and (*Z*)-stilbenes 19–22 as well as styrenes in a similar ratio previously observed for 10.

In order to study the chemical stability in comparison to similar N-mustards some amides and esters were prepared from acids 9a/9b. The coupling of an activated *p*-nitrophenyl ester²⁸ with diethylamine afforded amide 17. The corresponding 4-*tert*-butylphenyl ester 18 was synthesized in a similar manner. Chromatographic separation of the pure (*E*)-stilbene was possible, but BBr₃ treatment of 17 again gave a mixture of phenolic isomers. Careful analysis of the 400-MHz ¹H NMR spectrum showed the presence of about 60% of (*E*)-stilbene 17% of (*Z*)-stilbene, and 23% of styrenes. The easy *E*-*Z* isomerization of nonsteroidal estrogens is known,²⁹ but the isomerization to styrenes had no precedent. The extreme tendency of the unsymmetrically substituted DES derivatives toward double-bond isomerization made it necessary to liberate the phenols under much milder conditions.

The phenolic acid 10 (as a mixture of isomers) was silylated with *tert*-butyldimethylsilyl chloride and subsequent selective ester cleavage of a persilylated intermediate gave acid 26 that was the starting material for a number of acyl derivatives listed in Chart III. Methyl ether 27 was obtained on treatment of 26 with diazomethane, and the substituted phenyl esters 28–31 were prepared with DCCI in the coupling reaction of acid 26 with the corresponding phenols. The pentachlorophenyl ester 31 proved to be an excellent precursor for the further preparation of acyl amides. Treatment with diethanolamine afforded the bis(hydroxyethyl)amide 33 accompanied by some mono(hydroxyethyl) amide 32 from impurities of the diethanolamine. All of these phenyl esters and amides could be chromatographically purified to the pure (*E*)-stilbenes.

In order to investigate the biological activity and RBA of DNA intercalators linked to estrogens, the antitumor antibiotic daunorubicin was reacted with the activated ester 31 to afford the N-coupled adduct 34.

A number of DES derivatives were prepared from alcohol 35, which is readily available by lithium aluminum hydride reduction of pure (*E*)-stilbene ester 27. Mesylation of 35 gave mesylate 36. A carbamidic β-chloroethylamino function was introduced by using the method of Staab³⁰

Table I. Estradiol Receptor Binding Affinities of DES Derivatives

no.	R	RBA
41	daunomycin	no binding
10	COOH	0.1
24	(CH ₂) ₄ CH ₃	0.2
39	COOC ₆ Cl ₅	0.3
40	COOC ₆ H ₄ Cl	0.3
25	CON(C ₂ H ₅) ₂	1.0
44	CH ₂ OCONH(CH ₂) ₂ Cl	1.0
22	CH ₂ OC ₂ H ₅	1.2
19	CH ₂ OH	1.5
21	CH ₂ I	1.5
43	CH ₂ OSO ₂ CH ₃	1.8
20	CH ₂ Cl	3.0
23	CH ₃	10.0

by reaction of protected alcohol 35 with carbonyldiimidazole followed by treatment with β-chloroethylamine to afford 37. Fluoride deprotection of the isomerically pure (*E*)-stilbenes 26–29 and 34–37 gave the bisphenols 10, 38–40, and 41–44 containing less than 10% of isomeric (*Z*)-stilbenes and styrenes as shown by ¹H NMR. However, the compounds smoothly isomerized in aqueous solution to equilibrium of (*E*)- and (*Z*)-stilbenes and styrenes.

Estrogen Receptor Binding

Table I gives the relative binding affinity (*E*₂ = 100) for several of the synthetic DES derivatives. With the exception of the daunomycin derivative 41, which is totally devoid of binding affinity (RBA << 0.01), all compounds display a weak but substantial binding affinity. Interestingly, RBA values are drastically decreased by the presence of polar groups such as the carboxylic group in 10. Steric effects also decrease the affinity. Thus, esters of bulky alcohols such as 40 show only low RBA, and a difference was found between the smaller chloride 20 and the bulkier iodide 21. Similarly, compound 24 with a C₈ side chain shows very small receptor binding and the very bulky daunorubicin-linked DES derivative 41 shows none. In contrast, side chains comparable in size to the *n*-C₈H₁₇ group but with lone electron pairs that can form hydrogen bonds with water (ether 22, mesylate 43, and urethane 44) do not show a similar decrease in RBA. However, the observed structural influence of RBA cannot account for the isomerization that takes place with all of these derivatives in solution. The influence of these isomers (e.g. the styrenes) on the experimental conditions of the binding assay is not known. In addition, compounds with reactive groups may interact with proteins other than receptors, thereby reducing their concentrations as well as their binding potency. Binding affinity for such DES derivatives may therefore be significantly higher than expected from RBA values.

Experimental Section

General Procedures. Relative Binding Affinity for Estrogen Receptor. For details, see ref 31. Rat uterine cytosol was incubated at 18 °C for 30 min with 5 × 10⁻⁹ [³H]estradiol in the absence and presence of increasing amounts (10⁻⁹ to 10⁻⁵ M) of the test compound or unlabeled estradiol (control). Unbound

(28) Bodanszky, M.; du Voigneaud, V. *J. Am. Chem. Soc.* 1959, 81, 5688.

(29) Katzenellenbogen, J. A.; Carlson, K. E.; Katzenellenbogen, B. S. *J. Steroid Biochem.* 1985, 22, 589.

(30) Staab, H. A. *Angew. Chem.* 1962, 74, 407.

(31) Leclercq, G.; Deboel, M. C.; Heuson, J. C. *Int. J. Cancer* 1976, 18, 750.

compounds were then removed with dextran-coated charcoal, and the amounts of estrogen receptor bound [^3H]estradiol were measured. The relative concentrations of estradiol and test compound required to achieve 50% inhibition of [^3H]estradiol binding is the RBA; i.e. $\text{RBA} = ([I_{50}] \text{ estradiol} / [I_{50}] \text{ test compound}) \times 100$.

Chemical Methods. ^1H NMR spectra were recorded in CDCl_3 solutions with Me_4Si as internal standard if not otherwise stated (60 MHz, Varian T-60; 300 MHz, Bruker AM 300; 400 MHz, Bruker WM-400). IR spectra were recorded on Perkin-Elmer 157 G and 1420 instruments and UV spectra on a Beckman 5230 instrument. Mass spectra were obtained with AEI MS-9 (electron impact, 70 eV) and Kratos MS-50 (FAB) with Kratos MS-902 S (high resolution) instruments (numbers in brackets represent relative intensity). Melting points were determined on a Dr. Tottoli apparatus (Büchi). Silica gel 60 (Merck) and TLC plates from Schleicher & Schüll were used for chromatography. For difficult separations of (*E*)- and (*Z*)-isomers a special TLC technique with continuous flow of the eluant was used in which evaporation of the solvent from the open end of the chamber was permitted. The DES ethers showed absorptions in the IR spectra in the range of 2960–2830, 1608–1603, 1510–1501, 1283–1243, 918–912 (OSiMe_3), and 840–828 cm^{-1} (OCH_3). The UV spectra showed bands at λ_{max} ($\log \epsilon$) 210–208 (4.3), 236–230 (4.3), 274–267 (sh, 3.8), and 282–280 nm (sh, 3.6). The corresponding values for the DES derivatives are as follows: IR 3250–3240, 3035–3030, 2950–2820, 1610–1606, 1592–1570, 1510–1509, 837–831 cm^{-1} ; UV λ_{max} ($\log \epsilon$) 208–207 (4.2), 233–236 (4.2), 274–272 nm (sh, 3.7).

tert-Butyl 4-Iodobutylate (5). Phase-Transfer Procedure. A mixture of 80.00 g (0.45 mol) of *tert*-butyl 4-chlorobutylate,²² 136.00 g (0.9 mol) of sodium iodide, 14.20 g (0.17 mol) of sodium hydrogen carbonate, 4.80 g (0.01 mol) of tetrabutylammonium iodide, and 80 mL of water was stirred for 3 days at 70 °C. The mixture was poured on 200 mL of an aqueous sodium thiosulfate solution and extracted twice with 100 mL of diethyl ether. The organic phase was dried and distilled under vacuum to afford 79.74 g (66%) of 5, $\text{bp}_{0.02}$ 41 °C.

tert-Butyl 5,6-Bis(4-methoxyphenyl)octanoate (6). A solution of 50.00 g (0.195 mol) deoxyanisoin (4) and 72.00 g (0.270 mol) of iodo ester 5 in 600 mL of dry dimethylformamide (DMF) was added with stirring under nitrogen to a suspension of 9.00 g of sodium hydride (80%) in 50 mL of dry diethyl ether. The solution was stirred an additional 20 min and was then poured on 1 kg of ice-water and extracted with 500 mL of diethyl ether. The solution was dried (Na_2SO_4) and evaporated at reduced pressure. The product crystallized on addition of petroleum ether to afford 69.35 g (89%) of 6, mp 89–90 °C (lit.²² mp 89–90 °C).

(5*R,6*S**)-tert-Butyl 6-Hydroxy-5,6-bis(4-methoxyphenyl)octanoate (7) and (5*R**,6*R**)-tert-Butyl 6-Hydroxy-5,6-bis(4-methoxyphenyl)octanoate (8).** A Grignard reagent was prepared from 7.30 g (0.30 mol) of magnesium and 23 mL (0.30 mol) of ethyl bromide in 375 mL of dry diethyl ether. A solution of 60.00 g (0.15 mol) of ketone 6 in 500 mL of dry tetrahydrofuran (THF) was added, and the mixture was stirred for 3 h under nitrogen at 20 °C and was then hydrolyzed with 1 L of 10% aqueous ammonium chloride. The ethereal extract was dried and evaporated and the residue crystallized from diethyl ether/petroleum ether to afford 34.10 g of the pure threo isomer 7, mp 92–93 °C (lit.²² mp 83–84 °C). A mixture of isomers 7 and 8 crystallized on evaporation of the mother liquor (total yield 59.00 g, 7:8 = 4:1). Data for 7: IR (KBr) 3490–3430, 1705 ($\text{C}=\text{O}$), 1610, 1580, 1512 (Ar); ^1H NMR (400 MHz, CDCl_3) δ 0.71 (t, 3 H, 8-H), 1.22–2.15 (m, 8 H, 2-, 3-, 4-, 7-H), 1.37 (s, 9 H, *t*-Bu), 1.76 (s, 1 H, OH), 2.84 (dd, 1 H, 5-H), 3.74 (s, 3 H, OCH_3), 6.84 (d, J = 8.5 Hz, 2 H, Ar-H), 7.07 (d, J = 8.5 Hz, 2 H, Ar-H).

(*E*)- and (*Z*)-5,6-Bis(4-methoxyphenyl)-5-octenoic Acid (9a and 9b). Ten grams (23 mmol) of esters 7 and 8 and 0.5 of *p*-toluenesulfonic acid were heated to 110 °C. After 45 min the mixture was dissolved in 150 mL of dichloromethane and the organic solution was washed with water, dried, and evaporated to afford 7.7 g (94%) of an oil. The 60-MHz ^1H NMR spectrum was identical with literature data²² and the 400-MHz spectrum revealed the presence of 65% of (*E*)-stilbene and 20% of (*Z*)-stilbene and 15% of two styrenes.

9a: ^1H NMR (400 Hz, CDCl_3) δ 0.77 (t, 8- CH_3), 1.66 (quint, 3- CH_2), 2.12–2.20 (m, 2-, 4-, and 7- CH_2), 3.81 and 3.85 (2 s, OCH_3),

6.88–7.14 (2 AA'BB' systems). **9b:** ^1H NMR (400 Hz, CDCl_3) δ 0.92 (t, 8- CH_3), 2.31–2.36 (2 t of 2- CH_2), 2.52 (q, 7- CH_2), 2.58 (t, 4- CH_2), 3.71 (2 s, OCH_3), 6.60–6.86 (2 AA'BB' systems).

5,6-Bis(4-hydroxyphenyl)-5-octenoic Acid (10) (Ether Cleavage with KOH). A mixture of 1.0 g of acids 9a and 9b, 10 mL of ethylene glycol, and 2.00 g of KOH was heated in a cylindrical Teflon block with an air condenser at 200 °C for 2 days. The solution was diluted with cold hydrochloric acid and extracted twice with 100 mL of diethyl ether. The ^1H NMR spectrum of 10 was in agreement with the data obtained from BBr_3 cleavage of 9a and 9b:²² MS (150 °C) m/z 326 (M^+ , 100), 297 (24), 253 (36), 239 (71), 237 (54), 224 (33), 203 (34), 193 (43), 191 (43), 159 (35).

5,6-Bis(4-methoxyphenyl)-5-octenol (11). A solution of 1.00 g (2.8 mmol) of acid 9a/9b in 15 mL of dry THF was treated with 200 mg of lithium aluminum hydride. The mixture was hydrolyzed by careful addition of diluted sulfuric acid, and the products were isolated by extraction with diethyl ether to afford 0.90 g (94%) of alcohol 11 as an oil: ^1H NMR (60 MHz, CDCl_3) δ 0.76 and 0.93 (2 t, 3 H, 8- CH_3), 1.13–2.80 (m, 2-, 3-, 4-, 7- CH_2), 3.70, 3.768 3.83 (3 s, 6 H, OCH_3), 5.59 (q, vinylic-H), 6.53–7.23 (m, 8 H, Ar-H).

1-Chloro-5,6-bis(4-methoxyphenyl)-5-octene (12). A mixture of 148 mg (0.43 mmol) of alcohol 11, 200 mg of triphenyl phosphine, 5.5 mL of tetrachloromethane, 3 mL of THF, and 2 mL of acetonitrile was refluxed for 12 h. Triphenylphosphine oxide was filtered off and the product was purified by filtration through a short column of silica gel (eluant petroleum ether/acetone = 8:2) to afford 114 mg (73%) of an oil. Pure (*E*)-stilbene 12 was obtained from the zone of lowest polarity by TLC with continuous flow of the eluent: ^1H NMR (400 MHz, CDCl_3) δ 0.77 (t, J = 7.5 Hz, 3 H, 8- CH_3), 1.29 (tt, 2 H, 2- CH_2), 1.58 (quint, 2 H, 3- CH_2), 2.15 (q and t, 4 H, 4- and 7- CH_2), 3.32 (t, J = 7.0 Hz, 2 H, 1- CH_2), 3.83 (2 s, 6 H, OCH_3), 6.90–6.94 ($\text{A}_1\text{A}'_1 + \text{A}_2\text{A}'_2$ part, 4 H), 7.09–7.15 ($\text{X}_1\text{X}'_1 + \text{X}_2\text{X}'_2$ part, 4 H); MS (70 °C) m/z (M^+ , 48), 358 (M^+ , 100), 329 (15), 281 (73), 267 (43), 252 (44), 237 (27), 173 (52).

1-Iodo-5,6-bis(4-methoxyphenyl)-5-octene (13). A solution of 489 mg (1.4 mmol) of alcohol 11 and 1.56 g of *N*-methyl-*N*,*N*'-dicyclohexylcarbodiimidium iodide²⁷ in 15 mL of dry THF was stirred for 24 h. Fifty milliliters of ethyl acetate and a solution of sodium sulfite was added and the organic phase was dried and evaporated. Excess of the reagent was converted to *N*-acylurea by addition of trifluoroacetic acid and the iodide was purified by TLC to afford 333 mg (53%) of an oily mixture of isomers. Pure (*E*)-stilbene 13 was obtained by TLC (petroleum ether/ CH_2Cl_2 = 4:1) as described for 11: ^1H NMR (400 MHz, CDCl_3) δ 0.77 (t, J = 7.5 Hz, 3 H, 8- CH_3), 1.25 (quint, 2 H, 2- CH_2), 1.63 (quint, 2 H, 3- CH_2), 2.15 (q and t, 4 H, 4- and 7- CH_2), 2.96 (t, J = 7.0 Hz, 1- CH_2), 3.84 (2 s, 6 H, OCH_3), 6.89–6.93 ($\text{A}_1\text{A}'_1 + \text{A}_2\text{A}'_2$ part, 4 H), 7.09–7.14 ($\text{X}_1\text{X}'_1 + \text{X}_2\text{X}'_2$ part, 4 H).

1-Ethoxy-5,6-bis(4-methoxyphenyl)-5-octene (14). A solution of 154 mg (0.45 mmol) of 11 and 1 mL of ethyl iodide in 2 mL of dry DMF was treated with 30 mg of NaH. After 30 min, the mixture was poured on ice and extracted with diethyl ether. Filtration over a short silica gel column and evaporation gave 238 mg (82%) of 14 as a mixture of isomers: MS (90 °C) m/z 368 (M^+ , 79), 293 (29), 281 (44), 267 (76), 252 (39), 219 (40), 191 (40), 175 (46), 173 (52).

3,4-Bis(4-hydroxyphenyl)-3-octene (23). Deoxyanisoin (4; 1.30 g, 5 mmol) was alkylated with butyl bromide and reacted with ethylmagnesium bromide as described for 6 and 7 (compare ref 22 and 32). The threo/erythro mixture was dehydrated as described for 9 to afford methyl ether 15 that was deprotected with KOH as described for 10 to afford 470 mg (32%) of the crystalline (diethyl ether) bisphenol 23: mp 162–163 °C; ^1H NMR (400 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$) δ 0.70 (t, J = 7.0 Hz, 3 H, 8- CH_3), 0.76 (t, J = 7.5 Hz, 3 H, 1- CH_3), 1.05–1.20 (m, 4 H, 6- and 7- CH_2), 2.10 (t, J = 7.0 Hz, 2 H, 5- CH_2), 2.13 (q, J = 7.5 Hz, 2 H, 2- CH_2), 6.80 and 6.83 ($\text{A}_1\text{A}'_1 + \text{A}_2\text{A}'_2$ part, 4 H, Ar-H), 7.01–7.04 (m, $\text{X}_1\text{X}'_1 + \text{X}_2\text{X}'_2$ part, 4 H, Ar-H); MS (130 °C) m/z 296 (M^+ , 100), 281 (10), 267 (52), 253 (70), 239 (67), 224 (52), 210 (26), 195 (12).

(*E*)-3,4-Bis(4-hydroxyphenyl)-3-dodecene (24). Deoxy-

(32) Dodds, E. C.; Goldberg, L.; Lawson, W.; Robinson, R. *Proc. R. Soc. Ser. B* 1939, 127, 140.

anisoin (4; 1.30 g, 5 mmol) was converted to **24** as described for **23** with octyl bromide in the alkylation step to afford 510 mg (29%) of the (*E*)-stilbene **24**; mp 132 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.77 (t, *J* = 7.5 Hz, 3 H, 1-CH₃), 0.86 (t, *J* = 7.3 Hz, 3 H, 12-CH₃), 1.06–1.31 (m, 12 H, 6-, 11-CH₂), 2.09 (t, *J* = 7.5 Hz, 2 H, 2-CH₂), 2.13 (q, *J* = 7.5 Hz, 2 H, 5-CH₂), 6.80 and 6.84 (A₁A₁' + A₂A₂' part, 4 H, Ar-H), 7.04–7.07 (m, X₁X₁' + X₂X₂' part, 4 H, Ar-H); MS (110 °C) *m/z* 352 (M⁺, 100), 337 (3), 323 (15), 253 (79), 239 (45), 224 (25), 210 (8), 181 (7), 159 (45). Anal. (C₂₄H₃₂O₂) C, H.

***N,N*-Diethyl-5,6-bis(4-methoxyphenyl)-5-octenamamide (17)**. A solution of 4.00 g (11.3 mmol) of acids **9a/96b** and 1.60 g (11.5 mmol) of 4-nitrophenol in 30 mL of CH₂Cl₂ and 6 mL of dry THF was treated with 2.30 g of DCCI. The solution was stirred for 1.5 h at 20 °C and 3 mL of diethylamine was added. The solution was filtered, the solvent evaporated at reduced pressure, and the residue purified by filtration over a short silica gel column (petroleum ether/diethyl ether = 4:1) to give 2.3 g (50%) of oil **17** as a mixture of isomers. Separation of 40 mg into three fractions, (*E*)- and (*Z*)-stilbenes and styrenes, was effected by using the TLC technique with continuous flow of the eluants; ¹H NMR (400 MHz, CDCl₃) ((*E*)-stilbene) δ 0.78 (t, 8-CH₃), 1.00–1.15 (m, CH₃, *N*-ethyl), 2.05 (t, 2-CH₂), 2.15 (q, 7-CH₂), 2.16 (t, 4-CH₂), 2.25 (m), 3.09–3.36 (m, CH₂, *N*-ethyl), 3.81 (2 s, OCH₃), 6.58–7.14 (m, AA'XX' systems, Ar-H), ((*Z*)-stilbene) 0.93 (t, 8-CH₃), 2.55 (q, 7-CH₂), 2.60 (t, 4-CH₂), 3.69 (2 s, OCH₃), 6.58–7.14 (m, AA'XX' systems, Ar-H); MS (110 °C) *m/z* 409 (M⁺, 26), 381 (4), 340 (29), 294 (23), 279 (26), 265 (55), 260 (57), 250 (18), 239 (34), 237 (33), 223 (14), 207 (19). Anal. (C₂₈H₃₅NO₃) C, H, N.

4-*tert*-Butylphenyl 5,6-Bis(4-methoxyphenyl)-5-octenoate (18). A solution of 2.00 g (5.64 mmol) of acid **9a**, 0.86 g (5.73 mmol) of *tert*-butylphenol in 30 mL of CH₂Cl₂ was treated with 1.15 g (5.58 mmol) of DCCI and stirred for 3 h at 20 °C. The solution was filtered and evaporated to give 2.55 g (90%) of a crude mixture of isomers. (*E*)-Stilbene **18** was obtained by column chromatography on silicel gel (petroleum ether/acetone = 93:7) from the fraction of medium polarity (0.97 g, 35%): mp 80 °C; ¹H NMR (400 MHz, CDCl₃) δ 0.73 (t, *J* = 7.5 Hz, 3 H, 8-CH₃), 1.31 (s, 9 H, C(CH₃)₃), 1.62 (quint, *J* = 8.0 Hz, 2 H, 3-CH₂), 2.17 (q, *J* = 7.5 Hz, 2 H, 7-CH₂), 2.26 (t, *J* = 8.0 Hz, 2 H, 2-CH₂), 2.32 (t, *J* = 7.5 Hz, 2 H, 4-CH₂), 3.81 and 3.84 (2 s, 6 H, OCH₃), 6.79–6.83 (A₃A₃' part, 2 H, Ar-H), 6.89–6.94 (A₁A₁' + A₂A₂' part, 4 H, stilbene, Ar-H), 7.11–7.18 (X₁X₁' + X₂X₂' part, 4 H, stilbene, Ar-H), 7.31–7.35 (X₃X₃' part, 2 H, Ar-H); MS (170 °C) *m/z* 486 (M⁺, 83), 410 (12), 354 (11), 353 (11), 337 (14), 281 (16), 279 (17), 269 (23), 265 (19), 229 (65), 201 (24), 189 (20). Anal. (C₃₂H₃₈O₄) C, H, O.

1-Chloro-5,6-bis(4-hydroxyphenyl)-5-octene (20). A solution of 40 mg (0.11 mmol) of dimethyl ether **11** in 2 mL of CH₂Cl₂ was treated with 0.5 mL of BBr₃ at –10 °C as described in the literature²² to afford 21 mg (57%) of the bisphenol **20** as a mixture of isomers: ¹H NMR (90 MHz, CDCl₃/CD₃OD) δ 0.74 (t, 8-CH₃, (*E*)-stilbene), 0.91 (t, 8-CH₃, (*Z*)-stilbene), 1.11–2.66 (m, aliph CH₂), 1.46 (d, 8-CH₃, styrene), 3.30 (t, 1-CH₂, (*E*)-stilbene), 3.47 (t, 1-CH₂), 5.44 (t, vin H, styrene), 5.55 (q, vin H, styrene), 6.46–7.07 (m, Ar-H); MS (150 °C) *m/z* 330 (M⁺, 94), 315 (10), 303 (32), 301 (65), 253 (78), 239 (88), 224 (63), 210 (34), 159 (62), 145 (68). Anal. (C₂₀H₂₃O₂Cl) C, H, O, Cl.

1-Iodo-5,6-bis(4-hydroxyphenyl)-5-octene (21). Sixty-five milligrams (0.14 mmol) of **13** was deprotected with BBr₃²² to afford 57 mg of **21** (oil): ¹H NMR (400 MHz, acetone-*d*₆) δ 0.76 (t, 8-CH₃), 1.21–1.98 (m, aliph CH₂), 2.14 (t + q, 4- and 7-CH₂), 2.97 (t, 1-CH₂), 6.53–7.08 (m, Ar-H), MS (100 °C) *m/z* 422 (M⁺, 100), 407 (3), 393 (63), 253 (53), 239 (75), 224 (30), 210 (16), 159 (44), 145 (53). Anal. (C₂₀H₂₃O₂I) C, H, O, I.

1-Ethoxy-5,6-bis(4-hydroxyphenyl)-5-octene (22). Eighty-eight milligrams of **14** were deprotected as described for **10** to afford 58 mg (71%) of the ethyl ether **22**: ¹H NMR (400 MHz, acetone-*d*₆) δ 0.76 (t, *J* = 7.5 Hz, 8-CH₃), 1.05 (t, *J* = 7.0 Hz, OCH₂CH₃), 2.16 (q and t, *J* = 7.5 Hz, 4- and 7-CH₂), 3.18 (t, *J* = 6.5 Hz, 1-CH₂), 3.30 (q, *J* = 7.0 Hz, OCH₂CH₃), 6.84–7.07 (m, AA'XX' systems, Ar-H), 7.95–8.39 (phenol); MS (150 °C) *m/z* 340 (M⁺, 60), 265 (32), 253 (30), 239 (69), 224 (38), 223 (35), 205 (37), 161 (49), 159 (53), 145 (65). Anal. (C₂₂H₂₈O₃) C, H, O.

***N,N*-Diethyl-5,6-bis(4-hydroxyphenyl)-5-octenamamide (25)**. A solution of 100 mg (0.24 mmol) of **17** was deprotected with BBr₃

to afford 73 mg (78%) of the bisphenol **25** as a mixture of isomers: ¹H NMR (400 MHz, CD₃OD) δ 0.82 (t, 8-CH₃), 1.05–1.20 (m, CH₃, N(Et)₂), 1.31–1.88 (m, aliph CH₂), 2.14 (t, 2-CH₂), 2.23 (q, 7-CH₂), 2.25 (t, 4-CH₂), 3.20–3.38 (m, CH₂, N(Et)₂), 6.51–7.08 (m, Ar-H); MS (180 °C) *m/z* 381 (M⁺, 82), 353 (12), 352 (9), 266 (45), 248 (52), 247 (66), 246 (63), 237 (78). Anal. (C₂₄H₃₁O₃N) C, H, O, N.

5,6-Bis[4-(*tert*-butyldimethylsiloxy)phenyl]-5-octenoic Acid (26). A mixture of 0.90 g (2.76 mmol) of acid **10** and 1.90 g (12.6 mmol) of *tert*-butyldimethylsilyl chloride and 1.4 g of imidazole in 10 mL of DMF was stirred for 1 h. One milliliter of methanol was then added to cleave the silyl ester. The mixture was poured on ice, extracted with 200 mL of diethyl ether, washed twice with water, dried, and evaporated to afford 1.42 g (93%) of the bis(silyl ether) **26**. The product was characterized as its methyl ester **27**.

Methyl 5,6-Bis[4-(*tert*-butyldimethylsiloxy)phenyl]-5-octenoate (27). A solution of 50 mg of **26** in 2 mL of CH₂Cl₂ was treated with 1 mL of an ethereal diazomethane solution to afford the ester **27** quantitatively: ¹H NMR (400 MHz, CDCl₃) δ 0.22 (2 s, 12 H, SiCH₃), 0.75 (t, *J* = 7.5 Hz, 3 H, 8-CH₃), 1.00 (s, 18 H, SiC(CH₃)₃), 1.47 (quint, *J* = 7.5 Hz, 2 H, 3-CH₂), 2.07 (t, *J* = 8 Hz, 2 H, 2-CH₂), 2.12 and 2.13 (q + t, *J* = 7.5 and 7.0 Hz, 4 H, 4- and 7-CH₂), 3.54 (s, 3 H, CO₂CH₃), 6.79–6.83 (A₁A₁' + A₂A₂' part, 4 H, Ar-H), 6.98–7.02 (X₁X₁' part, 2 H, Ar-H), 7.02–7.05 (X₂X₂' part, 2 H, Ar-H); MS (150 °C) *m/z* 569 (M⁺, 14), 568 (M⁺, 31), 467 (6), 322 (39), 291 (15), 265 (100), 247 (25), 233 (26), 221 (86), 205 (32), 195 (24).

Phenyl 5,6-Bis[4-(*tert*-butyldimethylsiloxy)phenyl]-5-octenoate (28). A solution of 277 mg (0.5 mmol) of acid **26** and 0.55 mmol of phenol in 10 mL of dry THF was treated with 0.55 mmol of DCCI. The solution was filtered after 1 h, evaporated to dryness, and purified by column chromatography on silica gel (petroleum ether/diethyl ether = 96:4) to yield 142 mg (45%) of ester **28**: ¹H NMR (300 MHz, CDCl₃) δ 0.22 (2 s, SiCH₃), 0.77 (t, *J* = 7.3 Hz, 8-CH₃), 1.00 (2 s, SiC(CH₃)₃), 1.52–1.88 (m, aliph CH₂), 2.15 (q, *J* = 7.3 Hz, 7-CH₂), 2.24 (m, 4-CH₂), 2.32 (t, *J* = 7.5 Hz, 2-CH₂), 6.51–7.39 (m, Ar-H); MS (170 °C) *k/z* 630 (M⁺, 88), 602 (15), 467 (57), 383 (35), 339 (43), 329 (54), 301 (32), 287 (42), 271 (37), 259 (39), 249 (68), 247 (100), 235 (57), 221 (44), 205 (39), 189 (46), 177 (33).

4-Chlorophenyl 5,6-Bis[4-(*tert*-butyldimethylsiloxy)phenyl]-5-octenoate (29). **27** (277 mg, 0.5 mmol) was converted to 232 mg (70%) of **29** as described for **28**. The pure (*E*)-stilbene was obtained on TLC separation: ¹H NMR (400 MHz, CDCl₃) δ 0.22 (d, 12 H, SiCH₃), 0.77 (t, *J* = 7.5 Hz, 3 H, 8-CH₃), 1.01 (d, 1 H, SiC(CH₃)₃), 1.60 (quint, *J* = 7.6 Hz, 2 H, 3-CH₂), 2.16 (q, *J* = 7.5 Hz, 2 H, 7-CH₂), 2.25 (t, *J* = 7.7 Hz, 2 H, 4-CH₂), 2.31 (t, *J* = 7.5 Hz, 2 H, 2-CH₂), 6.80–6.85 (m, 6 H, Ar-H), 7.02–7.09 (m, 4 H, Ar-H), 7.27–7.31 (m, Ar-H); MS (150 °C) *m/z* 664 (M⁺, 100), 481 (20), 467 (16), 329 (63), 317 (17), 301 (24), 289 (28), 271 (21), 263 (26), 247 (68) 235 (52), 221 (28), 205 (29).

4-Nitrophenyl 5,6-Bis[4-(*tert*-butyldimethylsiloxy)phenyl]-5-octenoate (30). **26** (277 mg, 0.5 mmol) was converted to 270 mg (80%) of **30** as described for **29**. The pure (*E*)-stilbene was obtained on TLC separation: ¹H NMR (400 MHz, CDCl₃) δ 0.22 (d, 12 H, SiCH₃), 0.77 (t, *J* = 7.5 Hz, 3 H, 8-CH₃), 1.00 (d, 18 H, SiC(CH₃)₃), 1.62 (quint, *J* = 7.7 Hz, 2 H, 3-CH₂), 2.17 (q, *J* = 7.5 Hz, 2 H, 7-CH₂), 2.27 (t, *J* = 7.7 Hz, 2 H, 4-CH₂), 2.37 (t, *J* = 7.5 Hz, 2 H, 2-CH₂), 6.82 (t, 4 H, Ar-H), 7.02–7.09 (m, 6 H, Ar-H), 8.20–8.24 (m, 2 H, Ar-H); MS (170 °C) *m/z* 675 (M⁺, 81), 618 (13), 568 (10), 537 (10), 495 (3), 481 (34), 480 (29), 479 (47), 329 (55), 313 (22), 301 (59), 287 (42), 271 (30).

Pentachlorophenyl 5,6-Bis[4-(*tert*-butyldimethylsiloxy)phenyl]-5-octenoate (31). **26** (277 mg, 0.5 mmol) was converted to 363 mg (90%) of **31** as described for **28**. The pure (*E*)-stilbene was obtained on TLC separation: IR (CCl₄) 1787 cm⁻¹ (C=O, ester); ¹H NMR (400 MHz, CDCl₃) δ 0.21 (d, 12 H, SiCH₃), 0.76 (t, *J* = 7.5 Hz, 3 H, 8-CH₃), 1.00 (d, 18 H, SiC(CH₃)₃), 1.65 (quint, *J* = 7.7 Hz, 2 H, 3-CH₂), 2.15 (q, *J* = 7.5 Hz, 2 H, 7-CH₂), 2.27 (t, *J* = 7.7 Hz, 2 H, 4-CH₂), 2.43 (t, *J* = 7.5 Hz, 2 H, 2-CH₂), 6.81–6.85 (m, 4 H, Ar-H), 7.01–7.08 (m, 4 H, Ar-H); MS (170 °C) *m/z* 806 (M⁺, 33), 804 (M⁺, 79), 802 (M⁺, 100), 800 (M⁺, 57), 537 (37), 481 (63), 479 (49), 330 (96), 302 (49), 248 (94).

***N*-(2-Hydroxyethyl)-5,6-bis[4-(*tert*-butyldimethylsiloxy)phenyl]-5-octenamamide (32) and *N,N*-Bis(2-hydroxy-**

ethyl]-5,6-bis[4-(tert-butyl dimethylsiloxy)phenyl]-5-octenamide (33). A solution of 230 mg (0.29 mmol) of **31** in 5 mL of THF was treated with 1 mL of commercial diethanolamine for 12 h. After usual workup the crude mixture was separated by TLC to afford 43 mg of **32** (mp 117–119 °C) from the less polar zone and 82 mg of **33** (mp 132–133 °C) from the polar zone. Data for **32**: IR (CCl₄) 3440 and 3350 (N–H, amide), 1656 cm⁻¹ (C=O, amide); ¹H NMR (400 MHz, CDCl₃/D₂O) δ 0.23 (s, 12 H, SiCH₃), 0.74 (t, *J* = 7.5 Hz, 3 H, 8-CH₃), 1.00 (s, 18 H, SiC(CH₃)₃), 1.47 (quint, *J* = 7.6 Hz, 2 H, 3-CH₂), 1.96 (t, *J* = 7.7 Hz, 2 H, 2-CH₂), 2.13 (q and t, *J* = 7.5 Hz, 4 H, 4- and 7-CH₂), 3.24 (q, *J* = 7.5 Hz, 2 H, CONHCH₂CH₂OH), 3.57 (t, *J* = 5.2 Hz, 2 H, CONHCH₂CH₂OH), 5.59 (t, *J* = 5 Hz, 1 H, CONHR), 6.80–6.84 (m, A₁A₁' + A₂A₂' part, 4 H, Ar-H), 7.00–7.05 (m, X₁X₁' + X₂X₂' part, 4 H, Ar-H); MS (155 °C) *m/z* 597 (M⁺, 25), 579 (10), 494 (71), 465 (100), 348 (33), 330 (22), 249 (80), 232.5 (24). Anal. (C₃₄H₅₅NO₄Si₂) C, H, N, O, Si. Data for **33**: IR (CCl₄) 3380 (OH), 1623 cm⁻¹ (C=O, amide); ¹H NMR (400 MHz, CDCl₃) δ 0.22 (2 s, 12 H, SiCH₃), 0.74 (t, *J* = 7.5 Hz, 3 H, 8-CH₃), 1.00 (2 s, 18 H, SiC(CH₃)₃), 1.48 (quint, *J* = 7.6 Hz, 2 H, 3-CH₂), 2.09–2.18 (m, 6 H, 2-, 4-, and 7-CH₂), 3.28 (t, *J* = 5.2 Hz, 2 H, CONCH₂CH₂OH), 3.42 (t, *J* = 4.9 Hz, 2 H, CONCH₂CH₂OH), 3.62 (t, *J* = 5.2 Hz, 2 H, CONCH₂CH₂OH), 3.72 (t, *J* = 4.9 Hz, 2 H, CONCH₂CH₂OH), 6.79–6.82 (m, A₁A₁' + A₂A₂' part, 4 H, Ar-H), 7.00–7.06 (m, X₁X₁' + X₂X₂' part, 4 H, Ar-H); MS (170 °C) *m/z* 641 (M⁺, 12), 623 (22), 494 (100), 465 (100), 294 (45), 254.5 (37), 249 (65). Anal. (C₃₆H₅₉NO₅Si₂) C, H, N, O, Si.

Coupling of Daunorubicin to the Activated Octanoic Ester 31. A solution of 10 mg of daunorubicin hydrochloride, 0.2 mL of triethylamine, and 40 mg of ester **31** in 3 mL of dry THF was stirred for 17 h at room temperature. The reaction mixture was partitioned between water and diethyl ether. The ethereal solution was washed twice with ammonium hydrochloride solution, dried with Na₂SO₄, and evaporated. The residue was purified by preparative TLC (silica gel, CCl₄/CH₃OH) to afford 18 mg (94%) of adduct **34**: IR (CCl₄) 1715 (C=O), 1669 cm⁻¹ (C=O); ¹H NMR (400 MHz, CDCl₃) δ 0.20 (s, 12 H, SiCH₃), 0.72 (t, 3 H, CH₃), 1.00 (2 s, 18 H, SiC(Me)₃), 1.27 (d, 3 H, CH₃), 1.42 (quint, 2 H, CH₂), 1.62 (d, 1 H), 1.78 (dd, 1 H), 1.87 (t, 2 H, CH₂), 2.10–2.30 (m, 5 H), 2.43 (s, 3 H, COCH₃), 2.95 (d, 1 H), 3.25 (d, 1 H), 3.50–4.02 (1 H), 4.10 (s, 3 H, OCH₃), 4.20 (q, 1 H), 4.45 (s, 1 H, OH), 5.28 (s, 1 H), 5.47 and 5.50 (each s, each 1 H), 6.76 (t, 4 H), 7.00–7.02 (m, 4 H), 7.39 (d, 1 H), 7.39 (d, 1 H), 7.80 (t, 1 H), 8.07 (d, 1 H), 13.30 and 14.00 (each s, each 1 H, OH).

5,6-Bis[4-(tert-butyl dimethylsiloxy)phenyl]-5-octen-1-ol (35). A solution of 1.4 g (2.5 mmol) of acid **21** in 10 mL of dry THF was added to a -10 °C suspension of 0.3 g (7.9 mmol) of lithium aluminum hydride in 10 mL of dry THF. The mixture was stirred for an additional 10 min at room temperature and was then poured on ice and extracted with diethyl ether. The organic phase was washed with water, dried, filtered, and evaporated to dryness to afford 838 mg (62%) of a colorless oil. Column chromatography on silica gel (petroleum ether/ethyl acetate = 9:1) gave the pure (*E*)-stilbene **35**: ¹H NMR (400 MHz, CCl₄/D₂O) δ 0.23 (s, 12 H, SiMe), 0.76 (t, 3 H, CH₃), 1.01 (s, 18 H, SiCMe₃), 1.17–1.42 (m, 2 H, CH₂), 2.12–2.17 (m, 4 H, CH₂), 3.41 (t, 2 H, CH₂), 6.80–6.84 (m, 4 H, Ar-H), 7.01–7.06 (m, 4 H, Ar-H); MS (120 °C) *m/z* 540 (100 M⁺), 481 (15), 249 (18), 221 (15), 204 (19); exact mass calcd for C₃₂H₅₂O₃Si₂ 540.3455, found 540.3433.

5,6-Bis[4-(tert-butyl dimethylsiloxy)phenyl]-5-octenyl Methanesulfonate (36). A solution of 270 mg (0.5 mmol) of alcohol **35** in 5 mL of dry pyridine was treated for 10 min with a 5-fold excess of mesyl chloride. The solution was diluted with 50 mL of diethyl ether and extracted repeatedly with an aqueous solution of citric acid. The solution was dried with Na₂SO₄ and evaporated to dryness to afford 272 mg (88%) of an oil as an inseparable mixture of isomers: IR (CCl₄) 1173 (SO₂O), 912 cm⁻¹ (Si–O); ¹H NMR (60 MHz, CCl₄) δ 0.10, 0.16, 0.20 (each s, SiMe), 0.75 (t, 3 H, CH₃) 0.96 (br s, SiCMe₃), 1.16–2.26 (m, CH₂), 1.45 (d, styrene CH₃), 2.73–2.81 (several s, SO₃Me), 3.13–3.55 (m, benzylic CH₂), 3.80–4.20 (m, CH₂), 5.31–5.73 (m, vinylic styrene-H), 6.38–7.10 (Ar-H); MS (150 °C) *m/z* 618 (51, M⁺), 561 (24), 467 (78), 371 (62), 353 (63), 315 (37), 287 (47), 275 (56), 259 (48).

1-[[[5,6-Bis[4-(tert-butyl dimethylsiloxy)phenyl]-5-octen-1-yl]oxy]carbonyl]amino]-2-chloroethane (37). A solution of 75 mg (0.14 mmol) of alcohol **35** in 3 mL of dry THF was treated

with 25 mL (0.15 mmol) of carbonyldiimidazole. After 1 h of stirring at room temperature, 150 mg (1.45 mmol) of β-chloroethylammonium chloride followed by 1.5 mL of triethylamine was added. The mixture was stirred for 12 h and partitioned between diethyl ether and water. The ethereal solution was washed with water, dried with Na₂SO₄, and evaporated to afford 90 mg (100%) of an oil: IR (CCl₄) 3460 (NH), 1727 cm⁻¹ (urethane C=O), ¹H NMR (250 MHz, CDCl₃) δ 0.23 (s, 12 H, SiMe), 0.76 (t, 3 H, CH₃), 1.00 (s, 18 H, SiCMe₃), 1.14–1.22 (m, 2 H, CH₂), 1.32–1.45 (m, 2 H, CH₂), 2.08–2.17 (m, 4 H, CH₂), 3.44–3.66 (m, 4 H, CH₂), 3.87 (t, 2 H, CH₂), 4.95 (br 1 H, NH), 6.80–6.84 (m, 4 H, Ar-H), 7.00–7.05 (m, 4 H, Ar-H); MS (130 °C) *m/z* 645 (100, M⁺), 609 (15), 540 (68), 524 (65), 481 (21), 408 (17), 293 (27), 275 (68), 249 (76); exact mass calcd for C₃₅H₅₆NO₄Si₂Cl 645.3436, found 345.3429.

Methyl 5,6-Bis(4-hydroxyphenyl)-5-octenoate (38). A solution of 400 mg (1.23 mmol) of acid **10** in 10 mL of diethyl ether was treated for 5 min with an ethereal solution of diazomethane. The solvent was evaporated to afford 395 mg (95%) of ester **38** as a mixture of isomers. ¹H NMR (400 MHz, CD₃OD) δ 0.79 (t, 8-CH₃), 1.23–1.89 (m, aliph CH₂), 2.13 (t, 2-CH₂), 2.19 and 2.20 (q and t, 4- and 7-CH₂), 3.55 (s, CO₂CH₃), 6.52–7.06 (m, Ar-H); MS (100 °C) *m/z* 340 (M⁺, 97), 312 (25), 279 (51), 265 (22), 253 (44), 239 (95), 237 (83), 224 (46), 207 (53), 181 (35).

General Desilylation Procedure (Procedure A for Esters 28 and 29). A solution of 0.1 mmol of esters **28** and **29** in 2 mL of THF was treated with 1 mL of concentrated aqueous HF for 5 min. The mixtures were poured onto water and extracted with diethyl ether. The organic phases were washed with water, dried, and evaporated to dryness. The residues were purified by TLC to afford phenols **39** and **40** in 80–90% yield.

Phenyl 5,6-bis(4-hydroxyphenyl)-5-octenoate (39): IR (Et₂O) 3330 (OH), 1765 (C=O, ester), 1610 and 1590 cm⁻¹ (Ar); ¹H NMR (400 MHz, acetone-*d*₆) δ 0.77 (t, *J* = 7.5 Hz, 8-CH₃), 1.56–1.92 (m, aliph CH₂), 2.20 (q, *J* = 7.5 Hz, 7-CH₂), 2.31 (t, *J* = 7.0 Hz, 4-CH₂), 2.37 (t, *J* = 7.5 Hz, 2-CH₂), 6.56–7.41 (m, Ar-H), 8.02–8.27 (m, phenol H); MS (150 °C) *m/z* 402 (M⁺, 54), 340 (22), 279 (27), 253 (20), 251 (23), 239 (64), 237 (63), 225 (37), 215 (53), 173 (46), 159 (46), 145 (63), 135 (51), 133 (100), 121 (73), 107 (99), 94 (81). Anal. (C₂₆H₂₆O₄) C, H, O.

4-Chlorophenyl 5,6-bis(4-hydroxyphenyl)-5-octenoate (40): ¹H NMR (400 MHz, acetone-*d*₆) δ 0.77 (t, *J* = 7.5 Hz, 8-CH₃), 1.54–1.91 (m, aliph CH₂), 2.19 (q, *J* = 7.5 Hz, 7-CH₂), 2.30 (t, *J* = 7.5 Hz, 4-CH₂), 2.37 (t, *J* = 7.5 Hz, 2-CH₂), 6.55–7.14 (m, Ar-H), 7.36–7.45 (m, Ar-H), 8.00–8.42 (phenol H); MS (180 °C) *m/z* 438 (M⁺, 3), 436 (M⁺, 8), 239 (15), 237 (17), 215 (21), 189 (15), 173 (22).

General Desilylation Procedure for the Silyl Ethers 41–44 (Procedure B). A solution of the silyl ethers in THF was treated with ca. 100 mg of KF and 10 mg of 18-crown-6. A few drops of methanol were added, and the solution was stirred for 15–60 min (TLC monitoring). Workup was performed as described in procedure A.

Coupling product of the octanoic acid 10 to daunorubicin (41): yield 4.6 mg (98%); IR (KBr) 3420 (OH), 1715 (C=O amide), 1615 cm⁻¹ (C=O, quinone); ¹H NMR (400 MHz, CDCl₃/acetone-*d*₆) δ 0.65 (t, 3 H, CH₃), 1.20 (d, 3 H, CH₃), 1.38 (quint, 2 H, CH₂), 1.63–1.75 (m, 2 H, CH₂), 1.88 (q, 2 H), 2.35 (s, 3 H, COCH₃), 2.91 (d, 1 H), 3.18 (d, 1 H), 3.40 (m, 1 H), 4.03 (s, 3 H, OCH₃), 4.15 (q, 1 H), 5.20 (s, 1 H, 1-H), 5.41 (d, 1 H), 6.03 (d, 1 H, NH), 6.75 (m, 4 H, Ar-H), 6.93 (t, 4 H, Ar-H), 7.40 (d, 1 H, Ar-H), 7.75 (t, 1 H, Ar-H), 7.98 (d, 1 H, Ar-H), 13.28 and 13.96 (each s, each 1 H, OH); MS (FAB⁻) *m/z* 836 (M + H), 835 (M), 382, 381 (aglycon), 380; MS (FAB⁺) 838 (M + 3 H), 837 (M + 2 H), 836 (M + H).

5,6-Bis(4-hydroxyphenyl)-5-octen-1-ol (19): yield 3.65 g of an oil (mixture of isomers, quantitative); ¹H NMR (400 MHz, acetone-*d*₆/D₂O) δ 0.73 (t, 8-CH₃), 0.85 (t, 8-CH₃, styrene), 0.89 (t, 8-CH₃, (*Z*)-stilbene), 1.17–1.80 (m, CH₂), 1.45 and 1.87 (each d, CH₃, styrene), 2.13 (q and t, CH₂), 2.51 (q and t, CH₂, (*Z*)-stilbene), 3.38 (t, CH₂), 3.49 (m, CH₂), 5.51 (m, vinylic-H of styrenes), 5.56 (q, vinylic-H), 6.51–7.01 (m, Ar-H); MS (190 °C) *m/z* 312 (100, M⁺), 283 (20), 265 (26), 253 (60), 239 (83), 224 (48), 223 (47), 210 (26), 189 (21); exact mass calcd for C₂₀H₂₄O₃ 312.1725, found 312.1730.

5,6-Bis(4-hydroxyphenyl)-5-octenyl methanesulfonate (43): yield 167 (97%) of an oil; $^1\text{H NMR}$ (400 MHz, acetone- d_6) δ 0.76 (t, 8- CH_3), 0.88 (t, 8- CH_3 , styrene), 0.92 (t, 8- CH_3 , (*Z*)-stilbene), 1.30 (quint, CH_2), 1.47 (d, CH_3), 1.54 (quint, CH_2), 1.63-1.863 (m, CH_2), 1.90 (d, CH_3), 2.18 (q, 7- CH_2), 2.22 (t, 4- CH_2), 2.56 (q, 7- CH_2), (*Z*)-stilbene), 2.60 (t, 4- CH_2 , (*Z*)-stilbene), 2.98 (s, SO_3CH_3), 3.01 and 3.04 (each s, SO_3CH_3) 3.33 and 3.46 (each t, benzylic H), 4.03 (t, 1- CH_2), 4.15-4.22 (several t, 1- CH_2), 5.56 (t, vinylic styrene H), 6.54-7.09 (m, Ar-H), 8.1-8.3 (br, OH); MS (160 °C) m/z 390, (78, M^+), 294 (46), 279 (16), 265 (87), 253 (57), 239 (75), 237 (61), 223 (54), 181 (31), 171 (48); exact mass calcd for $\text{C}_{21}\text{H}_{26}\text{O}_5\text{S}$ 390.1501, found 390.1504.

2-[[[5,6-Bis(4-hydroxyphenyl)-5-octen-1-yl]oxy]carbonyl]amino]-2-chloroethane (44): yield 50 mg (93%) of an oil; IR (CHCl_3) 3450 (NH), 3330 (OH), 1710 cm^{-1} (urethane $\text{C}=\text{O}$); $^1\text{H NMR}$ (90 MHz, CDCl_3 , acetone- $d_6/\text{D}_2\text{O}$) δ 0.73 (t, 3 H, 8- CH_3), 1.11-1.55 (m, 4 H, CH_2), 2.00-2.24 (m, 4 H, CH_2), 3.33-3.66 (m, 4 H, $\text{NCH}_2\text{CH}_2\text{Cl}$), 3.87 (t, 2 H, 1- CH_2), 5.25 (t, 1 H, NH), 6.77-7.07 (m, 8 H, Ar-H); MS (200 °C) m/z 419 (41 5, M^+), 417 (100, M^+), 332 (25), 330 (74), 265 (44), 253 (59), 239 (66), 237 (74), 224 (26), 223 (20), 161 (60); exact mass calcd for $\text{C}_{23}\text{H}_{28}\text{NO}_4\text{Cl}$, 417.1707, found 417.1699.

Registry No. 1, 50-28-2; 3, 56-53-1; 4, 120-44-5; 5, 6182-78-1; 6, 67566-88-5; 7, 120743-85-3; 8, 120743-41-1; **9a**, 120743-42-2; **9b**, 120743-72-8; *E*-10, 120743-43-3; *Z*-10, 120743-73-9; *E*-11, 120743-44-4; *Z*-11, 120743-74-0; *E*-12, 120743-45-5; *Z*-12, 120743-75-1; *E*-13, 120788-27-4; *Z*-13, 120743-76-2; *E*-14, 120743-46-6; *Z*-14, 120743-77-3; *E*-17, 120743-47-7; *Z*-17, 120743-78-4; *E*-18, 120743-48-8; *E*-19, 120743-49-9; *Z*-19, 120743-79-5; *E*-20, 120743-50-2; *Z*-20, 120743-80-8; *E*-21, 120743-51-3; *Z*-21, 120743-81-9; *E*-22, 120743-52-4; *Z*-22, 120743-82-0; **23**, 120743-53-5; *E*-24, 120743-54-6; *E*-25, 120743-55-7; *Z*-25, 120743-83-1; *E*-26, 120771-41-7; *E*-27, 120743-56-8; *E*-28, 120743-57-9; *E*-29, 120743-58-0; *E*-30, 120771-42-8; 31, 120743-59-1; *E*-32, 120743-60-4; *E*-33, 120743-61-5; 34, 120743-62-6; *E*-35, 120743-63-7; *E*-36, 120743-64-8; *Z*-36, 120743-84-2; *E*-37, 120743-65-9; *E*-38, 120743-66-0; *Z*-38, 120771-43-9; *E*-39, 120743-67-1; *E*-40, 120743-68-2; 41·HCl, 120743-69-3; 43, 120743-70-6; 44, 120743-71-7; *p*- $\text{ClC}_6\text{H}_4\text{OH}$, 106-48-9; *p*- $\text{O}_2\text{NC}_6\text{H}_4\text{OH}$, 100-02-7; *tert*-butyl 4-chlorobutyrate, 3153-32-0; ethyl bromide, 74-96-4; octyl bromide, 111-83-1; 4-nitrophenol, 100-02-7; *tert*-butylphenol, 27178-34-3; pentachlorophenol, 87-86-5; diethanolamine, 111-42-2; daunorubicin hydrochloride, 23541-50-6; β -chloroethylammonium chloride, 870-24-6.

Hexestrol-Linked Cytotoxic Agents: Synthesis and Binding Affinity for Estrogen Receptors

Hannelore Köhle,[†] Karsten Krohn,^{*,†} and Guy Leclercq[‡]


Institut für Organische Chemie der Technischen Universität Braunschweig, Hagenring 30, D-3300 Braunschweig, Federal Republic of Germany, and Laboratoire de Cancérologie mammaire, Service de Médecine, Institut J. Bordet, 1000 Brussels, Belgium. Received August 16, 1988

With the *erythro*-hexestrol derivative **2** as the starting material, a variety of cytotoxic linked hexestrol (HEX) compounds were prepared including the HEX-N-lost derivative **36**, the HEX-(chloroethyl)nitrosourea **38**, the HEX-cyclophosphamide **44**, and the HEX-epoxide **68**. Relative binding affinity to estradiol receptors were in the magnitude of 1%, similar to that of comparable diethylstilbestrol compounds. HEX derivatives with long polyether spacers (**64**, **65**, **70**, **71**) showed no significant decrease in binding affinity in contrast to derivatives with other bulky side chains.

In the preceding paper¹ we outlined the general concept of linking cytotoxic groups to synthetic estrogens. The basic idea is to increase the specificity in the treatment of hormone-dependent cancers by reducing the systemic toxicity of the drugs (compare ref 2-4). A series of diethylstilbestrol (DES) derivatives were prepared and the receptor binding affinity was measured.¹ However, the chemical investigation revealed that unsymmetrically substituted DES derivatives equilibrate in solution to a mixture of the corresponding (*E*)- and (*Z*)-stilbenes and also, to some extent, to the two isomeric styrenes. It is known that hexestrol (HEX) has comparable binding affinity as DES,^{5,6} and we now present an extensive investigation on the chemical derivatization and binding properties of HEX derivatives. The chemically stable skeleton now allowed the synthesis of isomerically pure compounds and the attachment of highly reactive cytotoxic groups.

HEX derivatives that are substituted in the aromatic ring were obtained from the parent hexestrol.⁷⁻¹¹ Side-chain derivatives can be synthesized in a number of ways such as the condensation of 4-methoxybenzaldehyde with 4-methoxybenzyl cyanide,⁴ the addition of silylketene

Scheme I



acetals with allylsilanes,¹² or the Reformatsky¹³ or the McMurry reaction¹⁴⁻¹⁶ followed by hydrogenation. It is

[†] Institut für Organische Chemie der Technischen Universität Braunschweig.

[‡] Institut J. Bordet.

(1) Krohn, K.; Kulikowski, K.; Leclercq, G. *J. Med. Chem.* Preceding paper in this issue.

(2) Leclercq, G.; Heuson, J.-C. *Cancer Treat. Rep.* 1978, 62, 1255.